Disease Modeling and Therapeutic Strategies in CMT2A: State of the Art
Authors:
- 4 March 2019
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 56 (9) , 6460-6471
Abstract
Mitofusin 2 (MFN2) is a protein of the mitochondrial outer membrane that belongs to a family of highly conserved dynamin-related GTPases. It is implicated in several intracellular pathways; however, its main role is the regulation of mitochondrial dynamics, in particular mitochondrial fusion. Mutations in MFN2 are associated with Charcot–Marie–Tooth disease type 2A (CMT2A), a neurological disorder characterized by a wide spectrum of clinical features, primarily a motor sensory neuropathy. The cellular and molecular mechanisms by which MFN2 mutations lead to neuronal degeneration are largely unknown, and there is currently no cure for patients. Here, we present the most recent in vitro and in vivo models of CMT2A and the more promising therapeutic approaches under development. These models and therapies may represent relevant tools for the study and recovery of defective mitochondrial dynamics that seem to play a significant role in the pathogenesis of other more common neurodegenerative diseases.Keywords
Funding Information
- FP7 People: Marie-Curie Actions (RISE-2017-CROSS NEUROD)
This publication has 74 references indexed in Scilit:
- Axonal Transport Defects in a Mitofusin 2 Loss of Function Model of Charcot-Marie-Tooth Disease in ZebrafishPLOS ONE, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutationsNeurology, 2011
- MFN2 mutations cause severe phenotypes in most patients with CMT2ANeurology, 2011
- Mitofusin 2 Is Necessary for Transport of Axonal Mitochondria and Interacts with the Miro/Milton ComplexThe Journal of Neuroscience, 2010
- Comparative Transduction Efficiency of AAV Vector Serotypes 1–6 in the Substantia Nigra and Striatum of the Primate BrainMolecular Therapy, 2010
- Transduction of Nonhuman Primate Brain with Adeno-Associated Virus Serotype 1: Vector Trafficking and Immune ResponseHuman Gene Therapy, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006